Want to see CDNA full AI Analyst Report?
EarningsQ2 2026 Earnings Report
CDNA Q2 2026 EPS Results
Actual EPS$0.37
Consensus EPS$0.23
Beat/MissBeat by +$0.14
One Year Ago EPS-$0.16
CDNA Q2 2026 Revenue Results
Actual Revenue$131.95M
Expected Revenue$114.05M
Beat/MissBeat by +$17.90M
YoY Revenue Growth+52.23%
Earnings Announcement Details
QuarterQ2 2026
Date07/30/2026
TimeAfter Close
Conference CallThursday, July 30, 2026
CDNA Upcoming Earnings
CareDx's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
CDNA Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong organic and inorganic growth, material margin expansion, a fortified balance sheet, and substantive clinical and reimbursement milestones (Medicare LCD, KOAR data, AlloHeme and HistoMap publications). Key near-term risks include sizable operating expense run-rate, material out-of-period revenue that inflated reported margins this quarter, and execution/integration risk around the NavDx acquisition and specialty oncology ASP/margin improvement. Management raised 2026 guidance while taking a conservative approach to NavDx assumptions and flagged potential modest near-term investments that could temper margin expansion. Overall, the positives around revenue growth, cash position, clinical evidence, and coverage developments outweigh the operational and integration cautions.Company Guidance
Strong Top-Line Growth
Total revenue increased 52% year-over-year to $132.0M in Q2 2026, driven by testing services and other segments.
Testing Services Momentum
Testing services revenue rose 61% to $100.0M, with 58,000 tests performed (+17% volume) and reported revenue per test of $1,720 for the quarter.
Improved Profitability and Margins
Non-GAAP gross margin expanded to 74%. Non-GAAP gross profit grew 63% to $98M. Adjusted EBITDA increased by $19M to $25M (19% of revenue).
Raised Full-Year Guidance
2026 revenue guidance was raised to $490M–$500M (midpoint $495M, +30% YoY). Adjusted EBITDA guidance increased to $66M–$78M (midpoint $72M, ~15% of revenue).
Cash Position and Balance Sheet Strength
Ended quarter with $374M cash and cash equivalents, no debt; generated $31M cash from operations in the quarter and $94M over the last four quarters. Repurchased 570,000 shares for $12.2M.
Successful Divestiture and One-Time Gain
Closed sale of the lab products business on June 30, receiving $172M of consideration and recognizing a $113M GAAP gain (excluded from non-GAAP results).
Evidence and Clinical Validation Milestones
AlloHeme (cell therapy MRD) predicted relapse a median of 41 days earlier than clinical relapse in ACROBAT trial; manuscript submitted. HistoMap Kidney data showed >3x graft loss at six years in high‑risk vs low‑risk patients; clinical study launch planned this year and broader commercial availability targeted for 2027.
Expansion via NavDx Acquisition
Closed acquisition of NavDx (July 1); integration progress reported across commercial, Epic/workflow integration, and revenue cycle management. Early adoption signals: strong clinician interest at AHNS and supportive large-cohort data (~40,000 patients) demonstrating NavDx score prognostic utility.
Regulatory/Coverage Win
Medicare local coverage determination finalized, affirming surveillance coverage for kidney, heart, and lung molecular testing and establishing a pathway for HistoMap coverage and future organ expansions—reducing reimbursement uncertainty.
Clinical Adoption and Evidence Generation in Transplant
AlloSure highlighted in >30 abstracts and nine oral presentations at ATC. KOAR registry analyses: persistently elevated AlloSure associated with ~9x higher graft loss risk in one study and ~4–6x higher risk in a broader 1,250‑patient analysis—supporting longitudinal molecular monitoring adoption.
CDNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed